Memorial Sloan Kettering Cancer Center: Stomach Neoplasms trials

The registry lists 25 Stomach Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 3 are open to participants now and 5 have results posted.

Phase 1 5Phase 2 14No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07818018Phase 1/2
• A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction CancerRecruitingNCT07631000Phase 2
• A Study Collecting Health Information to Understand and Prevent Gastric CancerRecruitingNCT06370143
• A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative ResectionTerminatedNCT04510285Phase 2Results posted
• Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric CancerTerminatedNCT02726399Phase 2Results posted
• Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT00515411Phase 2Results posted
• Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and CisplatinCompletedNCT00397904Phase 2Results posted
• Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal AdenocarcinomaCompletedNCT00390416Phase 2Results posted
• A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
• A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction CancersActive, not recruitingNCT06243757
• Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal CancersCompletedNCT01213004Not applicable
• Quality of Life Among Long-Term Survivors of Resected Gastric CancerCompletedNCT00598546
• Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal TractActive, not recruitingNCT00582647
• Early Onset and Familial Gastric Cancer RegistryCompletedNCT00582257
• Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsCompletedNCT00580281Not applicable
• Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaCompletedNCT00074009Phase 2
• Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT00072332Phase 1
• BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With ChemotherapyCompletedNCT00017056Phase 2
• Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach CancerCompletedNCT00006038Phase 2
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal CancerCompletedNCT00005638Phase 1
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach CancerCompletedNCT00005599Phase 2
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal CancerCompletedNCT00003427Phase 1
• Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric CancerCompletedNCT00003055Phase 2
• Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach CancerCompletedNCT00002783Phase 2